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Background and purpose — Immediate postoperative pain man-
agement offered in knee arthroplasty is suboptimal in up to one-
third of patients resulting in high opiate consumption and delayed 
discharge. In this meta-analysis we investigate the analgesic effect 
and safety of perioperative adjuvant corticosteroids in knee 
arthroplasty.
Methods — Databases Medline, Embase, and Central were 
searched for randomized studies comparing the analgesic effect 
of adjuvant perioperative corticosteroids in knee arthroplasty. 
Our primary outcome was pain score at 24 hours postoperatively. 
Secondary outcomes included pain at 12, 48, and 72 hours, opiate 
consumption, postoperative nausea and vomiting, infection, and 
discharge time. Systemic (intravenous) and local (intra-articular) 
corticosteroids were analyzed separately.
Results — 14 randomized controlled trials (1,396 knees) were 
included. Mean corticosteroid dosages were predominantly 
50–75mg oral prednisolone equivalents for both systemic and 
local routes. Systemic corticosteroids demonstrated statistically 
signifi cant and clinically modest reductions in pain at 12 hours by 
–1.1 points (95%CI –2.2 to 0.02), 24 hours by –1.3 points (CI –2.3 
to –0.26) and 48 hours by –0.4 points (CI –0.67 to –0.04). Local 
corticosteroids did not reduce pain. Opiate consumption, postop-
erative nausea and vomiting, infection, or time till discharge were 
similar between groups.
Interpretation — Corticosteroids modestly reduce pain postop-
eratively at 12 and 24 hours when used systemically without any 
increase in associated risks for dosages between 50 and 75 mg oral 
prednisolone equivalents. 
■
Pain is one of the main reasons for hospital stay after knee 
arthroplasty; fi nding the best pain control regime postopera-
tively is therefore important (Husted et al. 2011, James Lind 
Alliance 2017). 
Traditionally pain control following surgery heavily relied 
on the use of systemic opiates, which are associated with 
multiple side effects including muscle weakness, light seda-
tion, and hypotensive effects, directly impacting postopera-
tive rehabilitation (Barletta 2012, Oderda 2012). Optimization 
of perioperative opiate analgesia has been shown to reduce 
length of stay and often improves patient satisfaction as well 
as reducing the incidence of chronic pain and functional out-
comes after surgery (Halawi et al. 2015, Meissner et al. 2015). 
At present, there is no consensus regarding the use of cor-
ticosteroids in the perioperative period following knee arthro-
plasty. It is not known whether they should be used as part of 
an enhanced recovery program, and if so, whether to adminis-
ter them systemically or locally. The objective of this system-
atic review is to assess the effect of adjunctive perioperative 
corticosteroids on postoperative pain in adult patients under-
going knee arthroplasty.
Methods
The prospectively registered protocol (PROPSERO - 
CRD42016049336) has been published (Mohammad et al. 
2017). The work follows the PRISMA guidelines.
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Inclusion and exclusion criteria
The inclusion criteria for studies were: (1) randomized con-
trolled trials (RCTs) investigating the effect of adjunctive 
perioperative corticosteroid on analgesic regimens in knee 
surgery (administered immediately before surgery or intraop-
eratively), (2) patients 18 years and over, (3) systemic (intra-
venous) or local (intra-articular) corticosteroid administration, 
and (4) anesthetic regimens must be the same for treatment 
and control groups. Exclusion criteria were: (1) corticosteroid 
administration through spinal/perineural/epidural space due to 
procedure-related confounding factors on pain, and (2) arti-
cles not available in the English language. 
Search strategy and study inclusion
An expert information analyst searched electronic databases 
(Medline [Ovid], Embase [Ovid] and Central [Cochrane 
Library]) from their inception to November 10, 2016. An 
updated search in September 2017 found no new RCTs had 
been published with pain as a primary outcome, making our 
search up to date. The full search strategies are available (see 
Supplementary data; Appendix: Search E1–3). Studies were 
assessed independently for inclusion by two authors (HRM 
and TWH). 
Outcome measures assessed 
Primary outcome was resting mean pain score at 24 hours fol-
lowing surgery (continuous variable). The secondary continu-
ous outcomes were mean pain score difference at 12, 48, and 
72 hours, mean opiate consumption (intravenous morphine 
equivalents) 24 hours postoperatively, and time till discharge. 
Secondary dichotomous outcomes were the incidence of post-
operative nausea and vomiting (PONV) during the fi rst 24 
hours postoperatively and incidence of reported infections.
The meaningful interpretation of the different corticoste-
roids and their dosages used in different studies was ensured 
by using well-established conversion charts (Hu 2010) to con-
vert them into oral prednisolone equivalents. 
We contacted included studies’ authors when data were 
missing or incomplete. If authors were unavailable we esti-
mated data where possible, using the recommendations in the 
Cochrane Handbook (Higgins et al. 2011). 
2 authors (HRM, TWH) independently assessed the risk of 
bias of included studies using the Cochrane Risk of Bias tool 
(Schünemann et al. 2011). The risk of publication bias could 
not be explored as there were less than 10 studies per outcome 
available. 
Data synthesis and analysis 
For continuous data, including data reported in scales, we 
used the inverse variance method to report the pooled mean 
difference (MD) and 95% confi dence interval (CI). Where 
data were reported in different scales, we used the standard-
ized mean difference (SMD) and CI in the analysis. All statis-
tically signifi cant pooled SMDs were back-transformed into 
the scale of interest (VAS 10 mm scale/intravenous morphine 
equivalents in our study). This was calculated by multiplying 
the pooled SMD by the largest study’s control group standard 
deviation (SD) of the said scale. We did not pool medians and 
interquartile range given this type of data is usually skewed 
and hence inappropriate for meta-analysis. For dichotomous 
outcomes we used the Mantel–Haenszel method, reporting the 
pooled risk ratio (RR) and CI. Signifi cance was set at p < 0.05 
(Oxman et al. 2004).
We expected high heterogeneity as a result of the differ-
ent pain scales and anesthetic regimens used by researchers. 
Hence we employed the random effects model in meta-analy-
sis to allow for heterogeneity. We used the I2 index to quantify 
heterogeneity, and we did not report the pooled result if it was 
substantial (I2 > 85%) and there was inconsistent direction of 
effect. The unit of analysis for pain and infection was the knee. 
For the outcomes postoperative nausea and vomiting, time till 
discharge, and opiate consumption the unit of analysis was 
the patient. 
We conducted analysis on the route of corticosteroid admin-
istration separately: systemic (intravenous) and local (intraar-
ticular). We carried out sensitivity analysis by temporarily 
removing studies at high risk of bias for blinding and allo-
cation concealment domains. Meta-analyses were conducted 
using Review Manager 5.3 (The Nordic Cochrane Centre; The 
Cochrane Collaboration). 
Funding and potential confl icts of interest
No specifi c funding was received for this research. Some of 
the authors have received or will receive benefi ts for personal 
or professional use from a commercial party (Zimmer Biomet) 
not related to this article.
Results
From 4,282 titles identifi ed, 14 studies (n  = 1,396 knees) met 
the inclusion criteria (Figure 1, Table 1, see Supplementary 
data). The vast majority of corticosteroids in oral predniso-
lone equivalents ranged between 50 mg and 75 mg for both 
systemic corticosteroids and local corticosteroids. This did not 
allow for dosage-related effects to be investigated given the 
tight dosage range. All corticosteroids were administered just 
before or during surgery. 
Sensitivity analyses did not raise any issues on the robust-
ness of the pooled results and hence have not been reported 
separately. Studies that did not report our outcomes of inter-
est in a format suitable for meta-analysis are summarized 
in Table 2 (see Supplementary data). Formats not suitable 
included studies reporting medians with interquartile ranges, 
given that this suggests the data are non-normally distributed 
making conversion to means and standard deviations contro-
versial (Higgins and Green 2011). Furthermore, papers only 
reporting means without standard deviations, standard errors, 
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tive nature (see Supplementary data, Appendix: Figure E1 
for analysis including Christensen et al. (2009)). Chia et al. 
(2013) showed evidence of reporting bias as they describe in 
the methods section that daily pain measurements were taken, 
but only reported pain at weekly intervals in the results. Wher-
ever meta-analysis is reported not possible, this is because less 
than 2 studies report the outcome.
Pain at 24 hours 
The systemic corticosteroid group (n  = 397, 3 studies: Jules-
Elysee et al. 2011, 2012, Koh et al. 2013) had signifi cantly 
lower pain compared with the control group SMD –0.73 (CI 
–1.3, –0.15; I2 = 83%; p = 0.01) equating to –1.3 points on 
VAS 10 mm scale (CI –2.3, –0.26). For local corticosteroids 
(n = 115, 2 studies: Koh et al. 2013, Ikeuchi et al. 2014) there 
were no statistical signifi cant differences in pain between 
them and their controls (Figure 3). 
Systemic corticosteroid studies which could not be included 
in meta-analysis (n = 138, 2 studies: Lunn et al. 2011, Kim et 
al. 2015) both demonstrated a reduction in pain scores at 24 
hours in steroid groups. Local corticosteroid studies (n = 172, 
2 studies: Seah et al. 2011, Yue et al. 2013) which could not 
be included in meta-analysis also demonstrated a reduction 
in pain scores at 24 hours (Table 2, see Supplementary data).
Pain at 12 hours 
There was a statistically signifi cant reduction in pain for sys-
temic corticosteroids (n = 128, 2 studies: Jules-Elysee et al. 
2011, 2012) SMD –0.54 (CI –1.08, 0.01; I2 = 58%; p = 0.05) 
equating to –1.1 VAS 10mm points (CI –2.16, 0.02) compared 
with control. It was not possible to meta-analyze local cortico-
steroids (see Supplementary data; Appendix: Figure E2). 
One systemic corticosteroid study that could not be included 
in meta-analysis (n = 90, 1 study (Kim et al. 2015) demon-
strated reduced pain in corticosteroid groups. 3 local cortico-
steroid studies (n = 247: Seah et al. 2011, Yue et al. 2013, 
Tsukada et al. 2016) of which 2 studies reported lower pain 
in the corticosteroid group (Table 2, see Supplementary data). 
Figure 1. PRISMA fl owchart of retrieved studies.
Records identified through
database searching
n = 4,282
Additional records identified
through other sources
n = 2
Duplicates removed
n = 1,345
Records excluded
n = 2,923
Full-text articles 
excluded
n = 2
SCREENING
IDENTIFICATION
ELIGIBILITY
INCLUDED
Records screened
n = 2,939
Full-text articles 
assessed for eligibility
n = 16
Studies included in
qualitative synthesis
n = 14
Studies included in
quantitative synthesis
(meta-analysis)
n = 14
Figure 3. Pain scores at 24 hours postoperatively. Note: First-named author only cited for each study
or confi dence intervals could not be included given that one 
of these is required with the mean for meta-analysis. All stud-
ies reported in Table 2 (see Supplementary data) fall into the 
above categories. 
Most studies scored low or unclear risk of bias in all domains; 
Figure 2 (see Supplementary data) shows graphically a sum-
mary of the risk of bias assessments. Only 2 studies demon-
strated evidence of high risk of bias in any domain. Chris-
tensen et al. (2009) reported broken blinding for 4 patients 
in the steroid group and hence this study was excluded from 
reported results involving pain outcomes, given their subjec-
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Pain at 48 hours 
Systemic corticosteroids demonstrated a statistically signifi -
cant reduction in pain (n = 329, 2 studies: Jules-Elysee et al. 
2011, Koh et al. 2013) –0.24 SMD (CI –0.46, –0.03’ I2 = 
0%; p = 0.03) equating to –0.4 VAS 10 mm points (CI –0.67, 
–0.04) (See supplementary data, Appendix: Figure E3). Meta-
analysis was not possible for local steroids.
Systemic corticosteroid studies that could not be included 
in meta-analysis (n = 138, 2 studies: Lunn et al. 2011, Kim et 
al. 2015) demonstrated reduced pain in corticosteroid groups. 
Local corticosteroid studies could not be included in meta-
analysis (n = 147, 2 studies: Yue et al. 2013, Tsukada et al. 
2016), 1 of which reported lower pain in the corticosteroid 
group (Table 2, see Supplementary data).
Pain at 72 hours 
Meta-analysis was possible only for local corticosteroids (n = 
115, 2 studies: Ikeuchi et al. 2014, Tsukada et al. 2016), show-
ing no statistically signifi cant difference in pain (see Supple-
mentary data; Appendix: Figure E4). Koh et al. 2013 (n = 269) 
report lower pain scores in the systemic steroid group. 
Postoperative nausea and vomiting 24 hours postop-
eratively
Both systemic corticosteroids (n = 112, 3 studies: Lunn et al. 
2011, Jules-Elysee et al. 2011, 2012) and local corticosteroids 
(n = 160, 2 studies: Kim et al. 2015, Tsukada et al. 2016) 
showed no statistically signifi cant differences in postopera-
tive nausea and vomiting between them and their controls (see 
Supplementary data; Figure 4). 
One systemic corticosteroid paper (Koh et al. 2013) could 
not be included in meta-analysis (n = 269) but reported fewer 
cases of postoperative nausea and vomiting in the corticoste-
roid group (Table 2, see Supplementary data). No gastrointes-
tinal complications were reported with corticosteroid use in 
any paper. 
Infection 
Systemic corticosteroid studies (n = 206, 3 studies: Jules-Ely-
see et al. 2011, 2012; Lunn et al. 2011) reported no infections 
in either intervention group. Koh et al. (2013) (n = 269) using 
systemic corticosteroids reported 1 infection in each group. 
In local corticosteroids (n = 325, 4 studies: Pang et al. 2008, 
Christensen et al. 2009, Seah et al. 2011, Chia et al. 2013) 
there was no signifi cant difference between groups (see Sup-
plementary data; Figure 5). 5 studies (Ng et al. 2011, Chia et 
al. 2013, Ikeuchi et al. 2014, Kim et al. 2015, Tsukada et al. 
2016) (n = 343) using local corticosteroids reported no infec-
tions in the control or corticosteroid groups. There were no 
other reported adverse effects associated with corticosteroid 
use in all shortlisted studies. Table 3 gives details of all infec-
tions reported. 
Opiate consumption 24 hours postoperatively 
No systemic corticosteroid studies reported this outcome in a 
format suitable for meta-analysis. In local corticosteroids (n = 
251, 3 studies: Pang et al. 2008, Christensen et al 2009, Kim 
et al. 2015) there were no signifi cant differences between the 
corticosteroid and control groups (see Supplementary data; 
Appendix: Figure E5). 
One systemic corticosteroid paper that could not be included 
in meta-analysis (n = 48, 1 study: Lunn et al. 2011) reported 
lower opiate consumption in the corticosteroid group. Local 
corticosteroid papers that could not be included in meta-anal-
ysis (n = 172, 2 studies: Seah et al. 2011, Yue et al. 2013) 
reported lower opiate consumption in corticosteroid groups 
(Table 2, see Supplementary data).
Mean time till discharge 
No statistically signifi cant differences in time till discharge 
were noted between systemic corticosteroid (n = 64, 2 stud-
ies: Jules-Elysee et al. 2011, 2012) and control groups (see 
Supplementary data; Appendix: Figure E6). Local corticoste-
roid meta-analysis was not possible. 
There was 1 systemic corticosteroid paper (Lunn et al. 
2011) that could not be included in meta-analysis (n = 48), 
which reported faster discharge times in the corticosteroid 
group by one day. There were 2 local corticosteroid studies 
(Christensen et al. 2009, Seah et al. 2011) that could not be 
included in meta-analysis (n = 175) that also reported faster 
discharge in the corticosteroid group by approximately 1 day.
Other unwanted side effects 
There were no cases of avascular necrosis reported in the 
included studies although we were severely limited by the 
short follow-up periods and number of patients. Only 2 stud-
ies reported the blood glucose levels of their patients. Jules-
Elysee et al. (2011) reported higher immediate postoperative 
Table 3. Details of infection cases reported from meta-analysis
Study Infection reported Details of infection
Chia et al. 2013 1 case in steroid arm (80 mg triamcinolone) Prosthetic joint infection
Christensen et al. 2009 1 case in steroid arm  Deep knee joint sepsis
Koh et al. 2013 1 case in steroid and 1 case in control arm Both cases periprosthetic joint infection
Pang et al. 2008 2 cases in steroid and 2 cases in control arm Both cases superfi cial wound infection which responded to antibiotics
Seah et al. 2011 1 case in steroid arm and 1 case in control arm  Both wound infection with sinus discharge
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mean glucose levels in the steroid group (133mg/dL) versus 
the control group (102mg/dL). Jules Elysee et al. (2012) 
reported higher immediate postoperative mean glucose levels 
in the steroid group at 128mg/dL compared with 101mg/dL in 
the control group. 
Discussion
To our knowledge no previous meta-analysis has explored the 
adjunctive effect of both systemic and local steroids in knee 
arthroplasty while allowing for heterogeneity. 
The minimum clinically signifi cant difference in resting 
pain scores reported is 0.9 points on the VAS 10 mm scale 
(Machado et al. 2015). Our meta-analysis found that systemic 
corticosteroids demonstrated reductions in resting pain at 12 
(1.1 points) and at 24 hours (1.3 points). Local corticoste-
roids did not provide any analgesic effect in knee arthroplasty 
although this may be due to our lower number in the meta-
analysis.
We found similar rates of postoperative nausea and vom-
iting, infection, time till discharge, and opiate consumption 
between the two groups. However, all the studies meta-ana-
lyzed for opiate consumption were local steroids. 
A systematic review by Tran and Schwarzkopf (2015) did 
not fi nd any evidence of an analgesic effect of local cortico-
steroid injections in knee arthroplasty. Additionally, no differ-
ences between the steroid and control groups were reported for 
infection and opiate consumption; this is in concordance with 
our work. 2 reviews observing the effects of systemic cortico-
steroid administration explored surgery as a whole rather than 
subgrouping analysis on specifi c procedures or even surgical 
specialties (De Oliveira et al. 2011, Waldron et al. 2012). Ana-
lyzing all surgical procedures as a whole incurs considerable 
clinical heterogeneity given that the surgeries vary drastically. 
Despite this limitation, De Oliveira et al. (2011) in their sys-
tematic review of systemic corticosteroids (intravenous dexa-
methasone) demonstrated a reduction in pain at 24 hours and 
no differences in infection between the corticosteroid and no-
corticosteroid groups. Waldron et al. (2012) in their systematic 
review of systemic corticosteroids (intravenous dexametha-
sone) in all surgical specialties found substantial reductions 
in pain at 24 hours and no increase in infection risk. Although 
the results of pain at 24 hours, infection risk, and opiate con-
sumption are in agreement with published fi ndings there are 
some differences. All the above reviews suggest faster dis-
charge times and reduced postoperative nausea and vomiting 
in the corticosteroid group, which we did not observe in our 
meta-analysis. This may be due to these studies using hetero-
geneous types of surgery and not using uniform time points 
in the analysis or due to studies being excluded from meta-
analysis that report a reduction.
Romundstad et al. (2004) conducted a double-blind RCT on 
intravenous corticosteroids (oral prednisolone equivalents of 
156 mg) 1 day after orthopedic surgery and found analgesic 
effects at 24 hours, and lower opiate consumption at 72 hours. 
This could perhaps suggest that it takes longer for the opiate 
reduction effect to become evident or that the doses of steroids 
in our meta-analysis were not high enough to elicit this effect. 
There are some limitations to our meta-analysis. There were 
not many studies using different doses of corticosteroids to 
allow meaningful evaluation of any dosage effects. Further-
more, there was substantial heterogeneity given the different 
scales used, anesthetic regimens, and patient demographic 
differences. The anesthetic regimens were, however, matched 
within each RCT. Although there was high heterogeneity in 
some of our analysis, all studies’ effect measurements were 
consistent in the same effect direction, varying in the strength 
of the effect. Furthermore, several studies did not report all of 
our outcomes of interest, clearly indicating there is no con-
sensus in the literature on what the important outcomes are 
and the measurement timing when exploring the effects of 
corticosteroids in surgery. There was a lack of reporting of 
patients’ blood glucose despite elevated blood glucose being a 
well-recognized side effect of corticosteroids. Another impor-
tant limitation is that studies used different corticosteroids. 
However, 12 of the 14 papers used short- to intermediate-act-
ing corticosteroids with a half-life from < 12 to 36 hours (Hu 
2010). Therefore, the time points we used were appropriately 
selected to investigate their effects. Finally, both studies by 
Jules Elysee et al. (2011, 2012) reported the average outcomes 
of bilateral total knee arthroplasty, which slightly violates an 
assumption of independent observations. However, given the 
steroids used are systemic and have systemic bodily effects we 
feel that clinically the knees would be affected independently. 
In summary our meta-analysis demonstrates that dosages 
between 50 and 75 mg of oral prednisolone equivalents of 
intermediate-acting systemic corticosteroids in knee arthro-
plasty provide a modest analgesic effect at 24 hours. Although 
we did not fi nd any evidence of an increased risk of infection 
with corticosteroids our analyses are underpowered to make 
any defi nitive conclusions. However, Jørgensen et al. (2017) 
published the largest cohort study to date (n = 3,927) inves-
tigating the effect of high-dose perioperative corticosteroids 
and found no differences in the incidence of deep infections 
between control and corticosteroid groups. We found no clini-
cally signifi cant analgesic effect for local steroids although 
this could be due to our analysis not being suffi ciently pow-
ered. Monitoring of blood glucose should be conducted in 
high-risk patients, i.e. diabetics, given evidence of elevated 
blood sugars with steroids. Diabetic patients would need to 
be advised to self-monitor their blood sugars on discharge and 
have medical follow-up in the community. There is a clear 
requirement for further research to investigate systemic ste-
roids in knee arthroplasty, as there are currently only sparse 
data on this issue. Additional work focusing on the effect 
of different dosages and specifi c corticosteroids would help 
develop consistent treatment guidance.
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Multimodal analgesia such as local infi ltrative analgesia has 
gained widespread popularity in recent years. Its usage as a 
basic pain treatment postoperatively could be improved by 
adjunctive use of systemic corticosteroids. 
Supplementary data 
Tables 1, 2, Figures 2, 4, 5, and an Appendix are available as 
supplementary data in the online version of this article, http://
dx.doi.org/ 10.1080/17453674.2017.1391409
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